Compare IDEXX Laboratories, Inc. (IDXX) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs LTC Properties Inc — how do they compare? IDEXX Laboratories, Inc. trades at $571.52 (market cap $46.22B), while LTC Properties Inc trades at $38.63 (market cap $2.05B). The key difference: IDEXX Laboratories, Inc. is far larger — about 22.5× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.98% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | LTC | |
|---|---|---|
Market Cap | $46.22B | $2.05B |
Sector | Health | Real Estate |
52-Week High | $766.68 | $42.81 |
52-Week Low | $526.44 | $33.98 |
Enterprise Value | $47.12B | $2.79B |
Dividend Yield | — | 5.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
LTC Properties trades at $38.77, down 1.65% on the day, with a bearish technical signal and mixed earnings history. The company reported revenue of $262.85 million in 2025, with a net income margin of 38.93%, and maintains a P/E ratio of 13.61. Recent news highlights active SHOP portfolio expansion, including a $95 million acquisition, and consistent monthly dividends of $0.19 per share.
Outlook remains cautious due to bearish technicals and mixed analyst sentiment, though strong profitability and dividend yield offer support. Key risks include execution of aggressive acquisition strategy and debt levels. Upside depends on sustained revenue growth and successful integration of new properties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
